Vontobel Holding 13F: Cuts Alcon (ALC) Stake by $53M

Vontobel Holding cut its stake in Alcon Inc. ALC by 815,507 shares during the quarter, according to a Form 13F filing with the SEC on October 16, 2026. The reduction amounted to a 14.4% drop in the firm's position, leaving it with 4,828,384 shares worth approximately $311.9 million at the close of the period. Shares of Alcon closed at $66.18 on the filing date.

ALC Alcon Inc.

$66.13 ▼ -14.36% year to date

1M 3M YTD

Daily close · Oct 19, 2026

What Changed in Vontobel Holding's Alcon Position

Vontobel trimmed its holdings from 5,643,891 shares down to 4,828,384 shares. This 14.4% reduction reflects a lighter allocation to the medical equipment provider during the period.

Other Institutional Activity in Alcon

Other large funds also adjusted their positions in the eye care specialist. Vanguard Group grew its holdings by 269,343 shares, ending with 21,464,480 shares worth about $1.45 billion. Aristotle Capital Management cut its stake by 481,233 shares, finishing with 10,584,374 shares valued at roughly $710.2 million. Legal & General Group grew its holdings by 53,234 shares to end with 3,950,897 shares worth about $267.1 million. Meanwhile, Vanguard Asset Management opened a new position with 2,074,627 shares worth approximately $141.3 million, and Schonfeld Strategic Advisors initiated a stake of 177,199 shares valued at about $11.9 million.

Alcon Inc. Stock Down 0.1%

Alcon shares recently traded around $66.13 as of October 20, 2026, which is about equal to the $66.18 close on the filing date. The stock trades below its 50-day moving average of $68.36 and its 200-day moving average of $72.42. The share price sits 24.5% below its 52-week high of $87.64 and 6.9% above its 52-week low of $61.84, while resting 20.1% below the average analyst price target of $82.73.

Recent Earnings

Alcon generated $10.86 billion in trailing twelve month revenue with a net profit margin of 5.9%. The company posted trailing earnings of $1.32 per share alongside a return on equity of 2.9%. Its next quarterly financial update is scheduled for November 10, 2026.

Dividend

Alcon pays an annual dividend of $0.36 per share, providing a dividend yield of 0.54% based on recent trading levels. The company maintains a dividend payout ratio of 26.6%, meaning it uses a modest share of its earnings to fund these shareholder distributions.

Analysts Set New Price Targets

Wall Street firms have active views on the stock. On August 12, 2026, JP Morgan maintained a neutral rating while adjusting its target to $78.40 from $77.53. Needham reiterated a buy rating with a $98.00 target on September 15, 2026. Jefferies maintained a buy rating on September 22, 2026, while lowering its target from $95.00 to $85.00. On October 7, 2026, Barclays initiated coverage with an equal-weight rating and a $70.00 price target. BTIG maintained a buy rating on October 12, 2026, while moving its target from $82.00 to $74.00. Overall, the stock carries a consensus buy rating and a mean price target of $82.73 across 16 analyst opinions.

About Alcon

Based in Geneva, Switzerland, Alcon operates as a global medical company focused on eye care. The firm develops surgical equipment such as intraocular lenses and diagnostic tools, alongside vision care consumables used by eye care professionals worldwide. Its products support treatments for cataracts, glaucoma, and refractive errors.

Bottom Line

Investors will watch for Alcon's upcoming earnings release on November 10, 2026, to gauge margin trends and revenue growth. Future institutional filings will also show whether other asset managers follow Vontobel in trimming exposure to the healthcare stock.